16:01 , Mar 26, 2018 |  BC Innovations  |  Translation in Brief

Tagging out

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray have demonstrated in a paper published in Nature Chemical Biology that targeted protein degradation can be used to create preclinical models that offer better control over...
01:10 , Dec 7, 2016 |  BC Extra  |  Clinical News

GNS identifies disease drivers from CoMMpass data

GNS Healthcare Inc. (Cambridge, Mass.) said it has identified four genes as "top drivers" of high-risk multiple myeloma. Using its machine learning technology, the company is collaborating with the Multiple Myeloma Research Foundation (MMRF) to...
08:00 , Dec 12, 2005 |  BioCentury  |  Tools & Techniques

Seeing is believing

Since the advent of X-rays at the end of the 19th century, physicians have used imaging to make diagnoses and to direct treatment strategies. But there is a growing realization that the value of imaging...
07:00 , May 6, 2002 |  BC Week In Review  |  Company News

MelTec other research news

Researchers published in the Journal of Theoretical Medicine the use of MELK technology to map protein networks involved in T cell invasion in sarcoid myopathy and polymyositis. Data showed certain cellular phenotypes were associated with...
07:00 , Apr 8, 2002 |  BC Week In Review  |  Company News

MelTec, MyoContract Pharmaceutical Reseach Ltd. deal

MyoContract will supply muscle cell cultures from normal and diseased tissues to MelTec, which will use its MELK systems biology and topological proteomics imaging technologies to develop assays for use in MyoContract’s discovery program in...
07:00 , Jul 9, 2001 |  BC Week In Review  |  Company News

MelTec other research news

MelTec published in IEEE Transactions the use of an algorithm with MelTec’s MELK technology to monitor fluorescent-labeled populations of lymphocytes in tissue samples. Meltec reported that the system correctly detected >95% of lymphocytes in tissue...